LONDON, March 14, 2014 /PRNewswire/ --
The trading session on Thursday, March
13, 2014 ended on a lower note as the Dow Jones Industrial
Average finished at 16,108.89, down 1.41% and the NASDAQ Composite
closed at 4,260.42, down 1.46%. The S&P 500 finished the
session 1.17% lower at 1,846.34. The losses were broad based as
nine of ten sectors ended the session in negative.
Investor-Edge.com looks at some of the equities which were most
active during the session. These include Cell Therapeutics Inc.
(NASDAQ:CTIC), Yandex N.V. (NASDAQ:YNDX), Himax Technologies Inc.
(NASDAQ:HIMX), and CytRx Corp. (NASDAQ:CYTR). Free research on
these four companies can be accessed at:
http://investor-edge.com/register
On Thursday, shares in Cell Therapeutics Inc. recorded heavy
trading as a total of 13.27 million shares changed hands, against a
three-month average volume of 5.68 million shares. The stock
finished the day at $3.94, down
3.90%, and at an intraday range of $3.87 and $4.22.
However, Cell Therapeutics Inc.'s shares have gained 4.51% in the
past three trading sessions, 15.88% in the last one month, and
106.28% on YTD basis. The S&P 500 Health Care Sector Index
mapped a gain of 1.14% in the last one month, while the NASDAQ
Composite Index went up by 0.47% during the same period. The stock
is trading above its 50-day and 200-day moving averages of
$3.28 and $1.90, respectively. The company's shares are
trading at an RSI of 65.41. Sign up and read the free notes on CTIC
at:
http://www.Investor-Edge.com/03142014/CTIC/report.pdf
Yandex N.V.'s stock saw heavy trading as a total of 15.16
million shares changed hands on Thursday, as compared with the
three-month average volume of 3.83 million shares. The stock closed
the day at $29.16, down 8.42%, after
trading between $28.65 and $31.60
during the session. Shares of the company traded at a PE ratio of
26.42. Yandex N.V.'s shares have lost 12.64% in the past three
trading sessions, 27.62% in the last one month, and 32.42% on YTD
basis. The S&P 500 Information Technology Sector Index mapped a
gain of 5.71% in the last three months, while the NASDAQ Composite
Index gained 6.48% during the same period. The stock is trading
below its 50-day and 200-day moving averages of $38.93 and $35.48,
respectively. The company's shares have an RSI of 32.09. The
complimentary notes on YNDX can be downloaded as in PDF format
at:
http://www.Investor-Edge.com/03142014/YNDX/report.pdf
Shares in Himax Technologies Inc. recorded heavy trading as a
total of 14.82 million shares changed hands on Thursday, as
compared with the three-month average volume of 8.14 million
shares. The stock ended the day at $14.74, down 5.81%, after fluctuating between
$14.59 and $16.15 during the session.
The company's shares traded at a PE ratio of 40.16. Himax
Technologies Inc.'s shares have declined 4.90% in the past three
trading sessions, while gaining 4.32% in the last one month, and
0.20% on YTD basis. The S&P 500 Information Technology Sector
Index declined 0.54% in the last one month, while the NASDAQ
Composite Index was up by 0.47% during the same period. Shares of
the company are trading above its 50-day and 200-day moving
averages of $14.06 and $9.77, respectively. The stock is trading at an
RSI of 64.73. Register for free on Investor-Edge and access the
latest research on HIMX at:
http://www.Investor-Edge.com/03142014/HIMX/report.pdf
CytRx Corp.'s shares saw heavy trading as a total of 11.07
million shares were exchanged, against a three-month average volume
of 3.97 million shares. On Thursday, the stock closed the day at
$4.17, down 12.76%, after vacillating
between $4.10 and $4.86. CytRx
Corp.'s shares have fallen by 18.24% in the past three trading
sessions, 33.60% in the last one month, and 33.49% on YTD basis.
The S&P 500 Health Care Sector Index mapped a gain of 9.22% in
the last three months, while the NASDAQ Composite Index was up by
6.48% during the same period. The stock is trading below its 50-day
moving average. CytRx Corp.'s 200-day moving average of
$3.58 is below the 50-day moving
average of $6.47. The company's
shares have an RSI of 32.11. The complete research on CYTR is
available for free at:
http://www.Investor-Edge.com/03142014/CYTR/report.pdf
About Investor-Edge.com
At Investor-Edge, we provide our members with a simple and
reliable way to leverage our economy of scale. Most investors do
not have time to track all publicly traded companies, much less
perform an in-depth review and analysis of the complexities
contained in each situation. That's where Investor-Edge comes in.
We provide a single unified platform for investors' to hear about
what matters. Situation alerts, moving events, and upcoming
opportunities.
=============
EDITOR NOTES:
=============
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] Investor-edge.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] Investor-edge.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] Investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge